Summit partner Akeso reports positive Phase III HARMONi-GI1 results for ivonescimab in biliary tract cancer

Summit Therapeutics Inc.

Akeso announced ivonescimab plus chemo showed statistically significant overall survival benefit vs durvalumab plus chemo in first-line advanced BTC.
HARMONi-GI1, a Phase III study in China sponsored by Akeso, also met key secondary endpoints of progression-free survival and objective response rate.
This is the first known Phase III study in advanced BTC to show OS superiority against an anti-PD-(L)1 plus chemotherapy regimen.
Detailed safety and efficacy results will be presented at an upcoming medical congress and published in a peer-reviewed journal.
Ivonescimab remains investigational in Summit's territories including U.S. and Europe; it is approved for NSCLC in China.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.